Sorafenat 200mg Tablet (Sorafenib)
Sorafenat 200mg Tablet contains Sorafenib, an oral targeted therapy used to treat liver cancer (hepatocellular carcinoma), kidney cancer (renal cell carcinoma), and thyroid cancer. It works by blocking tumor cell growth and angiogenesis.
- Estimated Delivery : Up to 4 business days
- Free Shipping & Returns : On all orders over $200
Overview:
Sorafenat 200mg Tablet is a tyrosine kinase inhibitor (TKI) containing Sorafenib. It is prescribed for patients with advanced liver cancer, renal cell carcinoma, and differentiated thyroid carcinoma that is refractory to radioactive iodine. Sorafenib works by inhibiting multiple protein kinases involved in tumor cell proliferation and blood vessel formation, slowing disease progression.
Uses:
Treatment of hepatocellular carcinoma (HCC) in adults.
Management of advanced renal cell carcinoma (RCC).
Treatment of differentiated thyroid carcinoma that is refractory to radioactive iodine.
Helps control tumor growth and reduce angiogenesis (blood vessel formation feeding tumors).
Dosage & Administration:
Take exactly as prescribed by your oncologist.
Usually taken twice daily on an empty stomach.
Swallow the tablet whole with water; do not crush or chew.
Avoid food for at least 1 hour before and 2 hours after dosing.
Precautions:
Inform your doctor if you have liver, kidney, or heart problems.
Regular blood tests and blood pressure monitoring are recommended.
Possible side effects include diarrhea, hand-foot skin reaction, fatigue, nausea, rash, hypertension, or low blood counts.
Avoid pregnancy during treatment and use effective contraception.
Store in a cool, dry place, away from light and moisture.
Why Choose Sorafenat 200mg Tablet?
Clinically proven targeted therapy for liver, kidney, and thyroid cancers
Oral capsule for convenient administration
Helps control tumor growth and angiogenesis
Trusted and widely prescribed worldwide
Package Includes:
Each pack contains 30 tablets of 200mg Sorafenat (Sorafenib)
















Reviews
There are no reviews yet.